Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mehran Elly

Diagnostic Radiology Rancho Mirage, CA Medical Doctor

NPI 1053361790 CMS profile 138648

39000 Bob Hope Dr, Eisenhower Imaging Center, Rancho Mirage, CA 92270

Open in the dashboard

General payments

$3,418

80 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mehran Elly of Rancho Mirage, CA is reported in the CMS Open Payments database as having received $3,418 across 80 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Diagnostic Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $929 13
2024 General $563 13
2023 General $878 12
2022 General $345 5
2021 General $218 10
2020 General $173 10
2019 General $313 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mehran Elly
  • Diagnostic Radiology median
  • Middle half of Diagnostic Radiology
  • National median

In program year 2025, general payments to Mehran Elly were reported at $929. Among 8,325 Diagnostic Radiology profiles paid that year, the median was $112 and the middle half received between $32 and $349.

Show as a table
Year Mehran Elly Diagnostic Radiology median Middle half National median
2019 $313 $108 $29–$318 $163
2020 $173 $65 $21–$252 $114
2021 $218 $92 $24–$292 $132
2022 $345 $104 $29–$294 $149
2023 $878 $110 $29–$337 $160
2024 $563 $113 $30–$356 $164
2025 $929 $112 $32–$349 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Siemens Medical Solutions USA, Inc. $955 35 payments
  2. Change Healthcare Technologies, LLC $410 3 payments
  3. Boston Scientific Corporation $382 9 payments
  4. Galvanize Therapeutics, Inc $360 4 payments
  5. Penumbra, Inc. $284 2 payments
  6. AngioDynamics, Inc. $236 4 payments
  7. Cleerly, Inc. $180 2 payments
  8. DePuy Synthes Sales Inc. $131 5 payments
  9. Stryker Corporation $104 4 payments
  10. Sirtex Medical Inc $98 1 payment
  11. Other $278 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,418 80 payments
Products named General payments · program years 2019–2025
  1. ALIYA SYSTEM $360 4 payments
  2. NAEOTOM Alpha $311 3 payments
  3. Indigo System $284 2 payments
  4. Change Healthcare Radiology Solutions $276 2 payments
  5. Cleerly Ischemia $180 2 payments
  6. Cleerly Labs $180 2 payments
  7. SPECT Symiba Intevo $179 9 payments
  8. BioFlo $170 3 payments
  9. SOMATOM AS $157 9 payments
  10. TheraSphere Y90 Glass Microspheres 7.0 GBq (US Commercial) $149 1 payment
  11. Other $1,623 61 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 167 billing codes

Paid by Medicare

$233,058

Of which drugs: $3,514

Medicare patients

1,005

Average age 77

Services billed

32,573

509 women, 496 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Ischemic heart disease 54%
Chronic kidney disease 38%
Atrial fibrillation 33%
Heart failure 31%
Diabetes 29%
COPD 27%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 330 29,256 $3,013
Injection, gadobutrol, 0.1 ml A9585 Office 21 1,865 $480

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

80 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Diagnostic Radiology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record